- Home
- SKYE vs SANG Comparison
SKYE vs SANG Comparison
Compare SKYE & SANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- SANG
- Stock Information
- Founded
- SKYE 2012
- SANG 1984
- Country
- SKYE United States
- SANG Canada
- Employees
- SKYE N/A
- SANG N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- SANG Computer Software: Programming Data Processing
- Sector
- SKYE Health Care
- SANG Technology
- Exchange
- SKYE Nasdaq
- SANG Nasdaq
- Market Cap
- SKYE 172.9M
- SANG 170.7M
- IPO Year
- SKYE N/A
- SANG 2021
- Fundamental
- Price
- SKYE $6.05
- SANG $5.28
- Analyst Decision
- SKYE Strong Buy
- SANG Buy
- Analyst Count
- SKYE 5
- SANG 2
- Target Price
- SKYE $18.40
- SANG $5.63
- AVG Volume (30 Days)
- SKYE 159.4K
- SANG 4.2K
- Earning Date
- SKYE 08-09-2024
- SANG 11-06-2024
- Dividend Yield
- SKYE N/A
- SANG N/A
- EPS Growth
- SKYE N/A
- SANG N/A
- EPS
- SKYE N/A
- SANG N/A
- Revenue
- SKYE N/A
- SANG $250,030,000.00
- Revenue This Year
- SKYE N/A
- SANG N/A
- Revenue Next Year
- SKYE N/A
- SANG $3.05
- P/E Ratio
- SKYE N/A
- SANG N/A
- Revenue Growth
- SKYE N/A
- SANG N/A
- 52 Week Low
- SKYE $1.44
- SANG $2.18
- 52 Week High
- SKYE $19.41
- SANG $6.40
- Technical
- Relative Strength Index (RSI)
- SKYE 50.99
- SANG 49.19
- Support Level
- SKYE $5.89
- SANG $5.15
- Resistance Level
- SKYE $7.11
- SANG $5.50
- Average True Range (ATR)
- SKYE 0.67
- SANG 0.16
- MACD
- SKYE 0.05
- SANG -0.02
- Stochastic Oscillator
- SKYE 23.33
- SANG 21.82
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable Internet protocol communications systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes Cloud Services, Video Conferencing, Carrier Services, Business Phone Systems, Phones & Devices, and Network Connectivity. The company sells into three major geographic centers: the United States of America, which is the key revenue driver, Canada, and other foreign countries.